Endomag Gains FDA Approval for Magtrace Liquid Marker

August 3, 2018

The FDA approved Magtrace’s non-radioactive liquid marker, used for mapping out lymph nodes during mastectomy procedures for breast cancer patients.

The marker is designed to follow the cancer cells’ most likely route they take when they spread out from the main tumor.

Surgeons using the company’s Sentimag platform in conjunction with Magtrace will be able to perform both lesion localization and sentinel node biopsy.

View today's stories